Charles River Laboratories International, Inc. (CRL)

Market Cap	10.23B
Revenue (ttm)	4.18B
Net Income (ttm)	484.03M
Shares Out	51.27M
EPS (ttm)	9.43
PE Ratio	21.17
Forward PE	18.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751,771
Open	196.07
Previous Close	198.15
Day's Range	192.40 - 202.78
52-Week Range	181.22 - 262.00
Beta	1.33
Analysts	Buy
Price Target	237.10 (+18.78%)
Earnings Date	Nov 1, 2023

About CRL

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 21,400
• Stock Exchange: NYSE
• Ticker Symbol: CRL

Financial Performance

In 2022, CRL's revenue was $3.98 billion, an increase of 12.31% compared to the previous year's $3.54 billion. Earnings were $486.23 million, an increase of 24.36%.

Analyst Forecast

According to 10 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is $237.1, which is an increase of 18.78% from the latest price.

Price Target

$237.1

(18.78% upside)

Analyst Consensus: Buy